{"database": "lobbying", "table": "lobbying_activities", "rows": [[2684159, "4094bd0e-dbac-41bb-be1e-29eea35ef496", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2021, "third_quarter", "PHA", "S.1391 - Fair Accountability and Innovative Research Drug Pricing Act.\nPrescription drug pricing issues.\nPatent abuse issues.\nEnsuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.\nDrug-price Transparency for Competition (DTC) Act.\nThe Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 110000, null, 0, 0, "2021-10-18T10:33:53.350000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2684159"], "units": {}, "query_ms": 54.112022975459695, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}